U.S., July 29 -- ClinicalTrials.gov registry received information related to the study (NCT07089719) titled 'Bevacizumab in Post-acute Sequelae of COVID-19 : Efficacy and Safety (Pilot Study)' on July 21.
Brief Summary: The aim of this research is to evaluate an innovative treatment, Bevacizumab, in patients suffering from respiratory complications related to COVID-19. These complications, particularly difficulty breathing (dyspnea) and impaired lung function, are common in some individuals after infection. The study seeks to determine whether Bevacizumab can improve breathing capacity by acting on vascular mechanisms that may be responsible for these issues. A total of 21 patients with these persistent symptoms will be included in the stu...